Pyrilutamide (KX-826) is a new topical medication with great promise for treating male pattern hair loss. It is a DHT blocker and has a similar structure to Dutasteride or RU58841.
Kintor Pharma of China has already started a phase 2 clinical trial in the US for men with AGA. The trial is a randomized, double-blind, vehicle controlled study to observe a change in target area hair count over 6 months.
Buy pyrilutamide is a brand new product for hair loss treatment. It is a topical solution that works by blocking the function of testosterone and DHT in the follicles. It is currently undergoing phase II clinical trials in both male and female patients with androgenic alopecia.
KX-826 (pyrilutamide) is a selective high-affinity silent antagonist of the androgen receptor developed by Kintor Pharmaceuticals. It is a member of the androgen receptor modulators family of drugs and was discovered through in-house discovery efforts.
It is a nonsteroidal antiandrogen and has demonstrated reasonable efficacy in the clinical trials conducted so far. It also does not decrease systemic androgen levels so it is unlikely to cause the unwanted side effects seen with oral 5-alpha reductase inhibitors like decreased libido, erectile dysfunction and depression.
The raw material pyrilutamide used in the production of PyriPure has been third-party lab tested and confirmed to be >99% pure. The pyrilutamide is then dissolved in propylene glycol and ethanol to make the 0.5% pyrilutamide solution that we sell.
Pyrilutamide (development code KX826) is a non-steroidal antiandrogen that acts as a selective high-affinity silent antagonist of the androgen receptor. It has been developed by Kintor Pharmaceuticals for the treatment of hair loss and acne.
Its clinical trials have shown that it is very effective in treating male pattern alopecia and has relatively few side effects. It has also been found to be safe in women.
The buy pyrilutamide from MV Supplements solution that we sell is made from pure pyrilutamide powder and contains a propylene glycol and ethanol vehicle, it can be stored in a dark place at room temperature. The pyrilutamide powder itself has been lab tested and confirmed to be >99% pure by a 3rd party.
Its mechanism of action on DHT is similar to that of finasteride and dutasteride, so it might be able to help some people who didn’t get positive results from these other products. Pyrilutamide is currently in phase II trials for hair loss, but it’s unclear whether it will be a successful alternative to finasteride or RU 58841.
Pyrilutamide is a new anti-androgen drug and has shown good results in clinical trials. It seems to work by blocking DHT from binding to the androgen receptor in follicles. It has the potential to be a great alternative for people who have side effects with finasteride and dutasteride.
In a press release Kintor Pharmaceuticals announced that pyrilutamide is currently undergoing phase 2 clinical trials for androgenetic alopecia in the US and China. The randomized, double-blinded, vehicle-controlled trial will be used to observe change in non-vellus hair count over 6 months of treatment.
Pyrilutamide powder is stable in a dry dark area or at 0 – 4 C for up to 1 year. It can also be made into a solution with ethanol or propylene glycol for use. The pyrilutamide solution should be stored in a dark place and kept away from sunlight. Water should be avoided as pyrilutamide can hydrolyze in an acidic or basic environment.
Pyrilutamide (development code KX-826) is a nonsteroidal antiandrogen (NSAA) – specifically, a selective high-affinity silent antagonist of the androgen receptor. It is being researched as a treatment for androgenic alopecia by Kintor Pharmaceuticals in the US and China.
A phase 2 trial of topical pyrilutamide has just been completed in China. This was a randomized, double-blind, placebo-controlled, parallel group, dose-escalation study with four cohorts receiving either pyrilutamide or a placebo twice daily for 6 months.
The results were impressive with a significant reduction in androgenic alopecia. It is expected to go into a larger, phase 3 clinical trial next year (2021). The drug has a similar structure to that of RU58841, a popular alternative to finasteride and dutasteride for hair loss. If the results of the phase 3 trials are good, it will be another option for people who can’t use finasteride or RU58841. Pyrilutamide is being developed as a first-in-class topical treatment for female pattern alopecia as well.